AXGN241115P12500
- 1.76
- +0.56+46.67%
AxoGen Newsroom
CCORF Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $17
JMP Securities Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $20
Raymond James Maintains AxoGen(AXGN.US) With Buy Rating, Raises Target Price to $18
JMP Securities Maintains Market Outperform on Axogen, Raises Price Target to $20
Axogen Analyst Ratings
Buy Rating Affirmed for AxoGen: Strong Q2 Performance and Strategic Leadership Amidst Market Growth Potential
Axogen Analyst Ratings
Raymond James Initiates Coverage On Axogen With Outperform Rating, Announces Price Target of $13
Axogen Analyst Ratings
Canaccord Genuity Reiterates Buy on Axogen, Maintains $15 Price Target
Buy Rating Upheld for AxoGen Amid Strong Financials and Innovative Growth Strategy
Axogen's Strong Growth Prospects and Positive Analyst Outlook Prompt Buy Rating and Increased Price Target
Buy Rating Affirmed: AxoGen's Robust Growth and Market Potential Drive Positive Outlook
Buy Rating Affirmed for AxoGen on Strong Clinical Results and Encouraging Sales Performance
Cantor Fitzgerald Reiterates Overweight on Axogen, Maintains $12 Price Target
Axogen Analyst Ratings
Analysts Offer Insights on Healthcare Companies: ScPharmaceuticals (SCPH), Alnylam Pharma (ALNY) and AxoGen (AXGN)
Buy Rating Affirmed for AxoGen on Strong Growth and Promising Market Prospects
Canaccord Genuity Reiterates Buy on Axogen, Maintains $11 Price Target
Axogen Analyst Ratings